-
Mashup Score: 0
Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.Results of the randomized phase 3 ZUMA-7 study showed the improvement in OS, a prespecified key secondary endpoint, among patients who were refractory to
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been approved for routine use in relapsed or refractory diffuse large B-cell lymphoma after UK data showed substantial improvement in overall survival and it was found to be cost-effective.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
News: NICE approves routine #NHS use of #CARTtherapy #axicabtageneciloleucel for diffuse large B-cell #lymphoma https://t.co/ars3n9GX26
-
Axicabtagene ciloleucel significantly extends survival in large B-cell lymphoma. https://t.co/4ZuqjVzcze #AxicabtageneCiloleucel @KitePharma @GileadSciences #HemOnc #OncAlert #MedEd